Cetirizine/Sodium-cromoglicate

Drug Profile

Cetirizine/Sodium-cromoglicate

Alternative Names: Sodium-cromoglicate/cetirizine

Latest Information Update: 24 Mar 2015

Price : *
* Final gross price and currency may vary according to local VAT and billing address.

At a glance

  • Originator Northwestern University
  • Developer INSYS Therapeutics, Inc
  • Class Acetic acids; Antiallergics; Benzopyrans; Chromones; Nonsedating antihistamines; Piperazines; Small molecules
  • Mechanism of Action Histamine H1 receptor antagonists; Mast cell stabilisers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Prostatitis

Most Recent Events

  • 24 Feb 2015 Gold Coast Therapeutics grants Insys an exclusive sub-license to develop a combination of cromolyn sodium and cetirizine
  • 24 Feb 2015 Preclinical trials in chronic Prostatitis in USA (unspecified route)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top